Akeso’s ivonescimab delivered a 34% overall survival improvement in an interim analysis of the China-based phase 3 Harmoni-6 trial, presented at ASCO. In previously untreated advanced squamous non-small cell lung cancer, ivonescimab plus chemotherapy reduced the risk of death versus a standard PD-1 inhibitor plus chemotherapy regimen used in the trial. The result—posted with a prespecified significance threshold—extends the bispecific’s earlier signal in progression-free survival from Chinese head-to-head studies. Oncologists said the OS readout could shape how the class is positioned, as VEGF-linked strategies have struggled to convert PFS advantages into durable survival benefits in first-line settings. Summit Therapeutics’ co-development involvement for ivonescimab outside China sets up a market test for how regulatory and evidence strategies differ by geography and trial design.